Lammert F, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 9
Paginas: 949-950
Archivo PDF: 106.95 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. D’Agnolo HM, Kievit W, Takkenberg RB, et al. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial. J Hepatol 2016; 65: 601-7.

2. Lazaridis KN, LaRusso NF. The Cholangiopathies. Mayo Clin Proc 2015; 90: 791-800.

3. Munoz-Garrido P, Marin JJ, Perugorria MJ, et al. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol 2015; 63: 952-61.

4. Iijima T, Hoshino J, Suwabe T, et al. Ursodeoxycholic Acid for Treatment of Enlarged Polycystic Liver. Ther Apher Dial 2016; 20: 73-8.

5. van der Feen C, van der Doef HP, van der Ent CK, Houwen RH. Ursodeoxycholic acid treatment is associated with improvement of liver stiffness in cystic fibrosis patients. J Cyst Fibros 2016: S1569-199330566-5.

6. Combes B1, Carithers RL Jr, Maddrey WC, et al. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1999; 29: 1649-54.

7. Fickert P, Wagner M, Marschall HU, et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130: 465-81.

8. Hayashi H1, Takada T, Suzuki H, Onuki R, Hofmann AF, Sugiyama Y. Transport by vesicles of glycine- and taurine-conjugated bile salts and taurolithocholate 3-sulfate: a comparison of human BSEP with rat Bsep. Biochim Biophys Acta 2005; 1738: 54-62.

9. Úriz M, Sáez E, Prieto J, Medina JF, Banales JM. Ursodeoxycholic acid is conjugated with taurine to promote secretinstimulated biliary hydrocholeresis in the normal rat. PLoS One 2011; 6: e28717.